冠状动脉内联合应用重组人尿激酶原和替罗非班对行急诊PCI的STEMI患者心肌血流灌注的影响

林东升; 傅广; 何仲春; 马丽霞; 罗辉; 王照飞

doi:10.13201/j.issn.1001-1439.2021.03.006

冠状动脉内联合应用重组人尿激酶原和替罗非班对行急诊PCI的STEMI患者心肌血流灌注的影响

- 长沙市第一医院心血管内科一病区(长沙, 410005)
基金项目:
长沙市第一医院2019年度院级科研基金项目(No:长一医发[2019]73号)

详细信息

通讯作者: 傅广,E-mail:929344850@qq.com

中图分类号: R541.4

收稿日期: 2020-08-16

Effects of intracoronary low-dose recombinant human prourokinase and tirofiban on myocardial perfusion in STEMI patients with primary PCI

- Department of Cardiology, The First Hospital of Changsha, Changsha, 410005, China

More Information

Corresponding author: FU Guang, E-mail: 929344850@qq.com

Received Date: 16 August 2020

摘要

摘要: 目的:探讨在ST段抬高型心肌梗死(STEMI)患者急诊行经皮冠状动脉介入治疗(PCI)过程中,冠状动脉(冠脉)内应用小剂量重组人尿激酶原联合小剂量替罗非班对心肌血流灌注以及预后的影响。方法:将76例STEMI患者随机分为联合用药组(36例)和替罗非班组(40例),联合用药组梗死相关动脉(IRA)内应用小剂量重组人尿激酶原(10~20 mg)联合小剂量替罗非班(0.1 mL/kg,5μg/kg),替罗非班组IRA内应用替罗非班(0.2 mL/kg,10μg/kg),然后两组患者分别行常规PCI治疗。比较两组患者术后心肌血流灌注、心肌梗死范围、临床预后以及1年随访结果等指标。结果:两组患者一般临床资料无统计学差异。联合用药组术后校正的TIMI帧数(cTFC)及肌酸激酶同工酶(CK-MB)峰值均明显低于替罗非班组(P<0.05),ST段回落大于50%的比例明显高于替罗非班组(P<0.05);两组患者住院期间出血事件发生率无统计学差异。1年随访,联合用药组患者N末端脑钠肽前体(NT-proBNP)水平明显低于替罗非班组(P<0.05),左室射血分数(LVEF)与左室舒张末期内径(LVEDD)缩小幅度明显高于替罗非班组(均P<0.05);两组患者主要不良心脑血管事件(MACCE)发生率相当。结论:冠脉内联合应用小剂量重组人尿激酶原和小剂量替罗非班可进一步改善STEMI患者心肌灌注水平,改善临床预后,且不增加住院期间出血风险。
- 急性ST段抬高型心肌梗死 /
- 经皮冠状动脉介入治疗 /
- 无复流/慢血流 /
- 重组人尿激酶原 /
- 替罗非班
Abstract: Objective: To observe the effects of intracoronary low-dose recombinant human prourokinase(rhPro-UK) and tirofiban on myocardial perfusion and prognosis in ST-elevation myocardial infarction(STEMI) patients with primary PCI.Methods: A total of 76 patients with STEMI were randomly divided into the combination group(n=36) and the tirofiban group(n=40). Patients in the combination group were treated with low-dose rhPro-UK(10-20 mg) and low-dose tirofiban(0.1 mL/kg, 5 μg/kg) in the infarct-related artery(IRA). In contrast, patients in the tirofiban group were treated with low-dose tirofiban(0.2 mL/kg, 10 μg/kg). Then all patients underwent primary PCI. Indicators of postoperative myocardial perfusion, myocardial infarction area, clinical prognosis, and 1-year follow-up were compared between the two groups.Results: There was no statistical difference in general clinical data between the two groups. Compared with the tirofiban group, the combination group had reduced corrected TIMI frame count(cTFC) and the peak of creatine kinase isoenzyme(CK-MB), but increased the number of ST-segment regression(STR) ≥50%(all P<0.05); There was no difference in the incidence of in-hospital bleeding events between the two groups. All patients were followed up for one year, compared with the tirofiban group, NT-proBNP level was lower, while left ventricular ejection fraction(LVEF) and the reduction of left ventricular end diastolic diameter(LVEDD) were higher in the combination group(all P<0.05); The incidence of major adverse cardiovascular and cerebrovascular events(MACCE) was comparable between the two groups.Conclusion: The combination of intracoronary low-dose rhPro-UK and tirofiban used in STEMI patients could further improve myocardial perfusion and clinical prognosis without increasing the risk of bleeding during hospitalization.
- acute ST-segment elevation myocardial infarction /
- percutaneous coronary intervention /
- no flow/slow reflow /
- recombinant human Prourokinase /
- tirofiban

HTML全文

参考文献(22)

[1]	Tasar O,Karabay AK,Oduncu V,et al.Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].Coron Artery Dis,2019,30(4):270-276.
[2]	赵甜甜,何壹娜.急性下壁心肌梗死患者行急诊PCI术中发生室性心动过速和心室纤颤的预测因素分析[J].临床急诊杂志,2020,21(5):363-368.
[3]	Li H,Fu DG,Liu FY,et al.Evaluation of related factors,prediction and treatment drugs of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction after direct PCI[J].Exp Ther Med,2018,15(4):3940-3946.
[4]	陈存芳,贾博,徐绍辉,等.经血栓抽吸导管注射重组人尿激酶原对高血栓负荷ST段抬高型心肌梗死患者急诊介入治疗效果的影响[J].临床心血管病杂志,2019,35(1):75-78.
[5]	郑海军,李爱琴,晋辉,等.经靶向灌注导管冠脉内应用重组人尿激酶原对STEMI并行急诊PCI患者的影响[J].中国新药杂志,2017,26(20):2463-2467.
[6]	林捷,颜彦,施鸿毓.胸痛中心建设对急性心梗救治效率及预后影响的研究[J].临床急诊杂志,2019,20(10):767-770.
[7]	Zencirci AE,Zencirci E,Değirmencioğlu A,et al.Predictive value of the no-reflow phenomenon and epicardial adipose tissue for clinical outcomes after primary percutaneous coronary intervention[J].Hellenic J Cardiol,2015,56(4):311-319.
[8]	Gupta S,Gupta MM.No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction[J].Indian Heart J,2016,68(4):539-551.
[9]	Asada Y,Yamashita A,Sato Y,et al.Thrombus formation and propagation in the onset of cardiovascular events[J].J Atheroscler Thromb,2018,25(8):653-664.
[10]	Heusch G,Skyschally A,Kleinbongard P.Coronary microembolization and microvascular dysfunction[J].Int J Cardiol,2018,258:17-23.
[11]	Su Q,Lv X,Sun Y,et al.Role of TLR4/MyD88/NF-κB signaling pathway in coronary microembolization-induced myocardial injury prevented and treated with nicorandil[J].Biomed Pharmacother,2018,106:776-784.
[12]	Geist B,LaRose A,Ueyama Y,et al.Serial coronary microembolization induced ischemic cardiomyopathy:Model refinement in the closed-chest Beagle dog[J].J Pharmacol Toxicol Methods,2019,99:106595.
[13]	Li X,Zhang S,Wang Z,et al.Platelet function and risk of bleeding in patients with acute coronary syndrome following tirofiban infusion[J].Front Pharmacol,2019,10:1158.
[14]	Zhang Z,Li W,Wu W,et al.Myocardial reperfusion with tirofiban injection via aspiration catheter:Efficacy and safety in STEMI patients with large thrombus burden[J].Herz,2020,45(3):280-287.
[15]	Zhang Y,Shao T,Yao L,et al.Effects of tirofiban on stent thrombosis,Hs-CRP,IL-6 and sICAM-1 after PCI of acute myocardial infarction[J].Exp Ther Med,2018,16(4):3383-3388.
[16]	Dannenberg L,Wolff G,Naguib D,et al.Safety and efficacy of Tirofiban in STEMI-patients[J].Int J Cardiol,2019,274:35-39.
[17]	Allencherril J,Jneid H,Atar D,et al.Pathophysiology,diagnosis,and management of the no-reflow phenomenon[J].Cardiovasc Drugs Ther,2019,33(5):589-597.
[18]	Yao Z,Li W,Cheng L,et al.Comparison of the effect of recombinant human pro-urokinase and tirofiban on myocardial blood flow perfusion in ST elevation myocardial infarction patients receiving primary percutaneous coronary intervention:A one-center retrospective observational study[J].Medicine(Baltimore),2019,98(27):e16143.
[19]	Zhao L,Zhao Z,Chen X,et al.Safety and efficacy of prourokinase injection in patients with ST-elevation myocardial infarction:phase IV clinical trials of the prourokinase phase study[J].Heart Vessels,2018,33(5):507-512.
[20]	白文楼,陈涛,孟存良,等.比伐卢定联合重组人尿激酶原对老年急性心肌梗死患者直接PCI术后慢血流/无复流的影响及安全性[J].临床心血管病杂志,2019,35(7):595-599.
[21]	Yang G,Wang W,Sheng X,et al.Tissue characteristics of culprit lesion and myocardial tissue-level perfusion in non-ST-segment elevation acute coronary syndromes:The EARLY-MYO-ACS study[J].Int J Cardiol,2019,287:32-38.
[22]	Ge H,Ding S,An D,et al.Frame counting improves the assessment of post-reperfusion microvascular patency by TIMI myocardial perfusion grade:Evidence from cardiac magnetic resonance imaging[J].Int J Cardiol,2016,203:360-366.